Auris Medical Holding AG Announces Pricing of Public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auris Medical Holding AG Announces Pricing of Public Offering of Common Shares

Basel, Switzerland, May 15, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (Nasdaq: EARS ), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, announced today the pricing of its previously announced public offering of 5,275,000 of its common shares at a public offering price of $4.75 per common share. In addition, Auris Medical has granted the underwriters an option to purchase up to 791,250 additional common shares at the public offering price, less underwriting discounts, to cover over-allotments. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $22.9 million. The offering is expected to close on or about May 20, 2015, subject to customary closing conditions.

Leerink Partners LLC is acting as sole book-running manager, JMP Securities LLC and Needham & Company, LLC are acting as lead managers and LifeSci Capital LLC is acting as co-manager in the proposed offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on May [14], 2015. The offering will be made only by means of a prospectus, copies of which may be obtained by contacting Leerink Partners LLP, Attention: Leerink Partners Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 800-808-7525 extension 6142, or by email at Syndicate@Leerink.com .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".

Forward-Looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's prospectus relating to its Registration Statement on Form F-1, as amended, and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contact: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, matthew@lifesciadvisors.com

Auris Medical Follow-On Pricing http://hugin.info/160190/R/1921792/688817.pdf

HUG#1921792

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 61

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 106

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center

Updated Category News Views 61

A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 104

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 182

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 66

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 173

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 125

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny

Updated Category News Views 140

Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...

Continue Reading

Top 5 Most Recently Viewed Articles

Ford Motor Company Faces Legal Challenges: Key Insights

Updated Category News Views 119

Understanding the Legal Landscape for Ford Motor Company As investors navigate the intricate world of stock ownership, recent events surrounding Ford Motor Company have raised eyebrows. The company currently finds itself at the center of a class action lawsuit involving shareholders who acquired stock during a specific period. Class Action Overview and Important Dates...

Continue Reading
Transforming the Specialty Fats and Oils Industry for Success

Updated Category News Views 188

A Deep Dive into the Specialty Fats and Oils Market The landscape of the specialty fats and oils market is rapidly transforming, growing from its valuation of US$ 16.12 billion in the preceding year to a staggering US$ 31.69 billion by 2033, marking a robust CAGR of 7.8% during the next financial stretch. This growth signals a significant shift in industry dynamics and...

Continue Reading
C3.ai: Analyzing Current Trends in the Options Market

Updated Category News Views 241

Current Sentiment on C3.ai Recently, well-known investors—often referred to as whales—have taken a decidedly negative stance towards C3.ai. This growing skepticism stems from the history of options involving the company's stock. An analysis of C3.ai's (AI) trading patterns uncovered nine notable trades. Digging deeper into these transactions shows that only 22% of...

Continue Reading
CytomX Therapeutics Completes $100 Million Stock Offering

Updated Category News Views 315

CytomX Therapeutics Completes $100 Million Stock Offering CytomX Therapeutics, Inc. (NASDAQ: CTMX), based in South San Francisco, has just announced the pricing of an extensive stock offering. The company is set to offer 76,923,076 shares of its common stock at a price of $1.30 per share. This significant transaction aims to raise approximately $100 million and is being...

Continue Reading
Wall Street's Bullish Coverage Initiation Highlights for NKE and Others

Updated Category News Views 120

Wall Street Analysts Initiate Coverage on Key Stocks In a dynamic market landscape, top analysts have recently adjusted their ratings on several prominent companies. Their insights provide a glimpse into potential future performance for investors. Today, we spotlight these analyst ratings and what they mean for some notable stocks. NIKE, Inc. (NKE) Coverage by Needham...

Continue Reading